- Home
- SGML vs LENZ Comparison
SGML vs LENZ Comparison
Compare SGML & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- LENZ
- Stock Information
- Founded
- SGML 2011
- LENZ 2019
- Country
- SGML Brazil
- LENZ United States
- Employees
- SGML N/A
- LENZ N/A
- Industry
- SGML Industrial Machinery/Components
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- SGML Industrials
- LENZ Health Care
- Exchange
- SGML Nasdaq
- LENZ Nasdaq
- Market Cap
- SGML 879.0M
- LENZ 819.1M
- IPO Year
- SGML N/A
- LENZ 2021
- Fundamental
- Price
- SGML $4.64
- LENZ $29.16
- Analyst Decision
- SGML Strong Buy
- LENZ Strong Buy
- Analyst Count
- SGML 2
- LENZ 5
- Target Price
- SGML $18.00
- LENZ $41.80
- AVG Volume (30 Days)
- SGML 1.6M
- LENZ 180.2K
- Earning Date
- SGML 05-14-2025
- LENZ 05-07-2025
- Dividend Yield
- SGML N/A
- LENZ N/A
- EPS Growth
- SGML N/A
- LENZ N/A
- EPS
- SGML N/A
- LENZ N/A
- Revenue
- SGML $152,515,393.00
- LENZ N/A
- Revenue This Year
- SGML $43.73
- LENZ N/A
- Revenue Next Year
- SGML $130.53
- LENZ $534.98
- P/E Ratio
- SGML N/A
- LENZ N/A
- Revenue Growth
- SGML 0.36
- LENZ N/A
- 52 Week Low
- SGML $4.53
- LENZ $14.42
- 52 Week High
- SGML $15.56
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- SGML 24.94
- LENZ 57.21
- Support Level
- SGML $5.23
- LENZ $28.14
- Resistance Level
- SGML $6.20
- LENZ $30.09
- Average True Range (ATR)
- SGML 0.50
- LENZ 1.51
- MACD
- SGML -0.12
- LENZ 0.01
- Stochastic Oscillator
- SGML 3.16
- LENZ 76.97
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.